Piper Sandler Maintains Neutral on Travere Therapeutics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Nicole Gabreski maintains a Neutral rating on Travere Therapeutics (NASDAQ:TVTX) and lowers the price target from $22 to $19.
August 18, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Travere Therapeutics and lowered the price target from $22 to $19.
The lowering of the price target by Piper Sandler from $22 to $19 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock price of Travere Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100